Short Interest in NewAmsterdam Pharma (NASDAQ:NAMSW) Expands By 21.0%

NewAmsterdam Pharma (NASDAQ:NAMSW) was the target of a large growth in short interest in June. As of June 15th, there was short interest totalling 12,100 shares, a growth of 21.0% from the May 31st total of 10,000 shares. Based on an average daily volume of 5,500 shares, the days-to-cover ratio is currently 2.2 days.

NewAmsterdam Pharma Stock Performance

NAMSW stock traded up $1.39 during midday trading on Tuesday, reaching $10.40. 8,765 shares of the company’s stock traded hands, compared to its average volume of 12,671. The firm’s fifty day moving average price is $9.22 and its 200-day moving average price is $8.69. NewAmsterdam Pharma has a 52 week low of $0.99 and a 52 week high of $14.67.

Institutional Trading of NewAmsterdam Pharma

An institutional investor recently raised its position in NewAmsterdam Pharma stock. Affinity Asset Advisors LLC increased its stake in NewAmsterdam Pharma (NASDAQ:NAMSW) by 47.9% during the first quarter, according to its most recent filing with the SEC. The fund owned 202,599 shares of the company’s stock after buying an additional 65,599 shares during the quarter. Affinity Asset Advisors LLC’s holdings in NewAmsterdam Pharma were worth $2,237,000 at the end of the most recent quarter.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.